CarlaRPh_TPA said:

For Half-life implications for missed, here is what the evidence says:The clinical trial data (STEP

I respect CarlaRPh_TPA perspective but I think this oversimplifies things a bit. Re: Half-life implications for — the subgroup analyses show meaningful heterogeneity.

I am not saying CarlaRPh_TPA wrong entirely — just that the picture is more nuanced than a blanket statement. The STEP data specifically shows dose-dependent variation.

Relevant to Half-life implications for — here is my latest bloodwork comparison:

Key improvements: A1C 7.6% → 5.5%, triglycerides 221 → 91 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you NurseLeah_Nash! This is incredibly helpful. Taking this to my next appointment. 🙏

Slightly tangential to Half-life implications but hannah_MT reminded me — does anyone have experience combining this with metformin?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Great discussion, everyone. Just a reminder to keep things civil and evidence-based.

Thread quality is excellent — keep it up. 👍